JUPITER NEUROSCIENCES, INC.
JUNSDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Oxygen at 1.5 ATA (atmospheres absolute). | Phase 2 | Traumatic Brain Injury | - | - |
Frequently asked questions
What is in JUPITER NEUROSCIENCES, INC.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in JUPITER NEUROSCIENCES, INC.'s (JUNS) pipeline across Phase 2. Its lead program is Oxygen at 1.5 ATA (atmospheres absolute). (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is JUPITER NEUROSCIENCES, INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for JUPITER NEUROSCIENCES, INC. (JUNS) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track JUNS biotech catalysts?→
Add JUNS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow JUPITER NEUROSCIENCES, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.